AstraZeneca has revealed it will acquire EsoBiotec for a total consideration of up to $1 billion.  The acquisition includes the company’s Engineered NanoBody Lentiviral (ENaBL) platform, which empowers the immune system to attack cancers.  ENaBL uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, such as T cells, which programme them to […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!